What is the 13F Pro Quality Score for IVVD?

13F Pro ranks Invivyd, Inc. (IVVD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IVVD's current score at https://13fpro.ai/research/IVVD (free sign-up required for the full ranking).

Which hedge funds own the most IVVD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IVVD include JANUS HENDERSON GROUP PLC, PERCEPTIVE ADVISORS, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IVVD as soon as new 13F filings post.

Where does 13F Pro source IVVD data?

All Invivyd, Inc. fundamentals and ownership data come directly from SEC EDGAR. Invivyd, Inc. files with the SEC under CIK 1832038. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IVVD in?

Invivyd, Inc. (IVVD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IVVD research updated on 13F Pro?

IVVD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Invivyd, Inc.(IVVD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1832038 IVVD stock profile & AI dashboard →

13F Pro Quality Score

25.7/100

Rank #2,535 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.3/100

Profitability

5.9/100

Balance Sheet

7.6/100

Earnings Quality

30.0/100

Free Cash Flow

5.4/100

Institutional Flow

6.8/100

Revenue Scale

11.1/100

Dilution Risk

8.6/100

IVVD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Invivyd, Inc. (IVVD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IVVD at 25.7/100 on a 32-signal composite quality model, placing it at rank #2,535 of 2,879 stocks — the bottom half of the AI-ranked universe. IVVD scores in the top quartile across revenue growth (93.3). Areas of concern include free cash flow (5.4) and profitability (5.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Invivyd, Inc. reports quarterly revenue of $13.7M, net income of $-41.4M, free cash flow of $-42.4M. Top institutional holders of IVVD by reported 13-F value include JANUS HENDERSON GROUP PLC, PERCEPTIVE ADVISORS, BVF /IL, based on the most recent SEC filings. IVVD trades on the Nasdaq exchange and files with the SEC under CIK 1832038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IVVD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Invivyd, Inc. directly from SEC EDGAR. Invivyd, Inc.'s 13F Pro composite quality score has ranged between 10 and 63 since 2025, currently 25.7 — a stable long-term trajectory across 20 quarterly and live scoring snapshots.

✦

Fun facts about Invivyd, Inc.

Quirks, history, and lore behind IVVD — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
With minimal revenue and a market cap in the tens of millions, this company lives on the razor's edge typical of early-stage biotech — burning cash in pursuit of the next big treatment.
3
The History
Spun out of Adimab and founded around 2020, it was built specifically to develop antibody-based therapies against infectious diseases — then the pandemic handed it a very urgent mission.
4
The Secret
The company focuses on engineered antibodies that are designed to stay effective even as viruses mutate — a direct response to the COVID-19 variant whack-a-mole problem.
5
The Lore
Its lead program targeted SARS-CoV-2 with a monoclonal antibody meant for immunocompromised patients who can't mount their own immune response to vaccines — a small but critically underserved population.
6
The Giveaway
The name is a mashup of "in vivo" and a nod to antibody science — this Waltham-based antibody shop trades under a ticker that rhymes with the sound you make when you've finally solved the puzzle.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$13.7M

Net Income

Q1 2026

$-41.4M

Free Cash Flow

Q1 2026

$-42.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$53.4MFY 2025

FY20 —FY23 $0.00FY25 $53.4M

Net Income

+73.6% YoY

$-52.5MFY 2025

FY20 —FY23 $-198.6MFY25 $-52.5M

Operating Income

+73.9% YoY

$-55.6MFY 2025

FY20 —FY23 $-212.8MFY25 $-55.6M

EPS (Diluted)

+83.4% YoY

$-0.30FY 2025

FY20 —FY23 $-1.81FY25 $-0.30

Total Assets

+20.8% YoY

$276.9MFY 2025

FY20 $117.4MFY23 $229.2MFY25 $276.9M

Op. Cash Flow

+66.4% YoY

$-58.1MFY 2025

FY20 —FY23 $-173.2MFY25 $-58.1M

Metric	FY 2025	FY 2023	FY 2020
Revenue	$53.4M	$0.00	—
Net Income	$-52.5M +73.6%	$-198.6M	—
Operating Income	$-55.6M +73.9%	$-212.8M	—
EPS (Diluted)	$-0.30 +83.4%	$-1.81	—
Total Assets	$276.9M +20.8%	$229.2M +95.2%	$117.4M
Operating Cash Flow	$-58.1M +66.4%	$-173.2M	—

AI Insight: IVVD Financial Trends

Invivyd's cash burn accelerated sharply in Q1 2026 despite modest revenue base, erasing prior-quarter momentum in operational efficiency.

• Revenue flat at $14M in Q1 2026 vs. $17M in Q4 2025; sequential decline marks reversal after three consecutive quarters of growth.

• Operating cash outflow doubled to $42M in Q1 2026 from $15M in Q4 2025, undoing six quarters of gradual burn reduction.

• Net loss widened to $41M in Q1 2026 from $11M in Q4 2025, largest quarterly loss since Q3 2024.

⚠ Equity surged to $203M in Q1 2026 from $93M in Q3 2025, likely via capital raise, masking underlying cash burn deterioration.

⚠ Operating margin gap persists: Q1 2026 op income of -$43M on only $14M revenue suggests unprofitable unit economics.

AI Insight: IVVD Ratio Trends

Invivyd swung from deepening losses through mid-2025 toward material margin recovery, but Q1 2026 reversal signals early-stage volatility in profitability path.

• Operating margin improved sharply from -149.7% in Q1 2025 to -73.0% in Q4 2025, the best quarterly result in dataset.

• Net profit margin similarly narrowed from -144.1% in Q1 2025 to -64.3% in Q4 2025, indicating operational leverage gaining traction.

• Q1 2026 shows deterioration: OpMargin missing; ROE collapsed to -81.6% from -18.3%; ROA dropped to -68.5% from -16.0%.

⚠ Quarterly profitability metrics remain highly volatile and deeply negative; path to breakeven remains uncertain despite Q4 2025 improvements.

⚠ Q1 2026 reversal suggests Q4 2025 gains may not be sustainable; monitor next quarter for trend confirmation.

Get alerted when IVVD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Invivyd, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IVVD

JANUS HENDERSON GROUP PLC
$42.9M33,094,330 sh
PERCEPTIVE ADVISORS LLC
$27.1M20,859,303 sh
BVF INC/IL
$25.4M19,525,000 sh
MAVERICK CAPITAL LTD
$24.7M18,970,913 sh
Saturn V Capital Management LP
$14.2M10,949,084 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.1M10,074,326 sh
M28 Capital Management LP
$12.0M9,248,250 sh
EVENTIDE ASSET MANAGEMENT, LLC
$11.8M9,071,995 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$11.0M8,436,894 sh
Soleus Capital Management, L.P.
$10.0M7,708,727 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$42.9M	33,094,330
PERCEPTIVE ADVISORS LLC	$27.1M	20,859,303
BVF INC/IL	$25.4M	19,525,000
MAVERICK CAPITAL LTD	$24.7M	18,970,913
Saturn V Capital Management LP	$14.2M	10,949,084
VANGUARD CAPITAL MANAGEMENT LLC	$13.1M	10,074,326
M28 Capital Management LP	$12.0M	9,248,250
EVENTIDE ASSET MANAGEMENT, LLC	$11.8M	9,071,995
DRIEHAUS CAPITAL MANAGEMENT LLC	$11.0M	8,436,894
Soleus Capital Management, L.P.	$10.0M	7,708,727

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IVVD on your watchlist

Track score changes the day Invivyd, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IVVD a good stock to buy?

13F Pro's AI-powered analysis of Invivyd, Inc. (IVVD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IVVD are available on the IVVD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IVVD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IVVD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Invivyd, Inc.'s investment landscape.